CymaBay Therapeutics to Present at Upcoming Investment Conferences

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced its participation in two upcoming healthcare conferences: the Credit Suisse 31st Healthcare Conference on November 8, 2022, and the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. At both events, management will engage in fireside chats to discuss the company’s innovative therapies for liver diseases, particularly focusing on seladelpar, a treatment for primary biliary cholangitis (PBC). Webcasts for both presentations will be available through CymaBay's investor relations page.

NEWARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Credit Suisse 31st Healthcare Conference taking place November 7-10, 2022 in Rancho Palos Verdes, CA and the 34th Annual Piper Sandler Healthcare Conference taking place November 29 to December 1, 2022 in New York, NY.

Credit Suisse 31st Healthcare Conference
Date:	Tuesday, November 8
Time:	1:25 – 1:55 pm Pacific Time
Format:	Fireside Chat
Webcast:	http://ir.cymabay.com/events

34th Annual Piper Sandler Healthcare Conference
Date:	Thursday, December 1
Time:	10:30 – 10:55 am Eastern Time
Format:	Fireside Chat
Webcast:	http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Cautionary Statements
Any statements made in this press release and at the conferences referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, the timing of the release of seladelpar clinical data, the future adoption and utilization of currently approved therapies, the anticipated evolution of the PBC treatment paradigm, future therapeutics, surrogate endpoints, potential target product profiles and potential quality of life benefits are forward-looking statements that are subject to risks and uncertainties. Actual outcomes and results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of product development activities; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of product candidates; and the ability to obtain sufficient financing to complete development, regulatory approval and commercialization of product candidates. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:                                    

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

When will CymaBay participate in the Credit Suisse 31st Healthcare Conference?

CymaBay will participate in the Credit Suisse 31st Healthcare Conference on November 8, 2022.

What time is CymaBay's presentation at the Credit Suisse Conference?

CymaBay's presentation at the Credit Suisse Conference is scheduled for 1:25 PM to 1:55 PM Pacific Time.

What is the focus of CymaBay at the Piper Sandler Healthcare Conference?

At the Piper Sandler Healthcare Conference on December 1, 2022, CymaBay will discuss its innovative therapies for liver diseases.

Where can I find the webcast for CymaBay's presentations?

The webcasts for both CymaBay presentations can be found on their investor relations page at http://ir.cymabay.com/events.

What is seladelpar and its significance to CymaBay?

Seladelpar is a first-in-class treatment for primary biliary cholangitis (PBC) that has received breakthrough therapy designation from the U.S. FDA.